P. Kottaridis

发表

Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial

S. Grace, J. North, M. Lowdell, 2015, PloS one.

Comparative analysis of melphalan versus busulphan T‐cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia

G. Mufti, S. Mackinnon, K. Peggs, 2019, British journal of haematology.

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study

N. Russell, G. Cook, D. Marks, 2010, Bone Marrow Transplantation.

The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.

J. Delgado, M. Jarmulowicz, S. Mackinnon, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dual Glutathione‐S‐Transferase‐θ1 and ‐μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia

M. Pirmohamed, R. Clark, T. Holyoake, 2014, Clinical pharmacology and therapeutics.

Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19

A. Khwaja, Rajeev Gupta, A. Fielding, 2020, British journal of haematology.

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

S. Mackinnon, K. Peggs, P. Ell, 2010, Blood.

Role o f N onmyeloablative A llogeneic S tem-Cell Transplantation A fter F ailure o f A utologous Transplantation i n P atients W ith L ymphoproliferat ive Malignancies

C. Craddock, S. Mackinnon, D. Linch, 2002 .

Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.

C. Craddock, S. Mackinnon, D. Linch, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

I. Kayani, S. Mackinnon, K. Peggs, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

R. Hills, S. Langabeer, D. Linch, 2005, Blood.

Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1‐mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID‐19 pandemic

P. Kottaridis, N. Farah, R. Baker, 2020, British journal of haematology.

Development of Squamous Cell Carcinoma of the Skin During Induction Chemotherapy for Acute Myeloid Leukemia

A. Goldstone, P. Kottaridis, 2002, Leukemia & lymphoma.

Cavernosal arterial insufficiency and metabolic syndrome probably represent a common pathology of endothelial dysfunction in recipients of high-dose therapy and stem-cell transplantation.

R. Chatterjee, P. Kottaridis, K. Palla, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)

S. Papageorgiou, P. Kottaridis, K. Cwynarski, 2013, Bone Marrow Transplantation.

patients, excluding acute promyelocytic leukemia, from the UK MRC transplantation in acute myeloid leukemia (AML): an analysis of 1135 No evidence that FLT3 status should be considered as an indicator for

R. Hills, D. Linch, R. Gale, 2008 .

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

R. Hills, A. Pizzey, K. Mills, 2005, Blood.

University of Birmingham Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

A. Khwaja, E. Morris, H. Stauss, 2013 .

Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication

A. Mead, A. Khwaja, D. Linch, 2008, British journal of haematology.

Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia.

C. Craddock, S. Mackinnon, K. Peggs, 2001 .

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

C. Craddock, M. Labopin, A. Nagler, 2022, Bone Marrow Transplantation.

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

J. Esteve, A. Ganser, M. Labopin, 2022, Bone Marrow Transplantation.

Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring

S. Mackinnon, K. Peggs, A. Goldstone, 2000 .

The Allogeneic Effect in Non-Hodgkin's Lymphoma

A. Goldstone, P. Kottaridis, 2003, Leukemia & lymphoma.

K. Peggs, S. Ings, A. Goldstone, 2000, Blood.

Survival and Freedom from Progression in Autotransplant Lymphoma Patients is Independent of Stem Cell Source: Further Follow-up from the Original Randomised Study to Assess Engraftment

N. Schmitz, P. Dreger, D. Linch, 2002, Leukemia & lymphoma.

Intensive Chemotherapy Is Associated With Poor Overall Survival in Autoimmune Disease-associated Myeloid Malignancies

A. Khwaja, R. Hough, M. Mansour, 2018, HemaSphere.

Interleukin‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement

P. Kottaridis, T. Fox, B. Carpenter, 2020, British journal of haematology.

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

J. Garcia-conde, C. Craddock, S. Mackinnon, 2002, Blood.

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

C. Craddock, S. Mackinnon, K. Peggs, 2002, Blood.

Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia

R. Benjamin, S. Mackinnon, K. Peggs, 2013, British journal of haematology.

A case of ‘red eye’ post allogeneic stem cell transplantation

A. Castleton, P. Kottaridis, 2007, Bone Marrow Transplantation.

Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortality

C. Fegan, S. Mackinnon, G. Hale, 2002, British journal of haematology.

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

A. Pettitt, C. Crawley, J. Snowden, 2010, Blood.

Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation

P. Griffiths, S. Grace, S. Mackinnon, 2010, Transplantation.

Preservation of fertility in women undergoing reduced-intensity conditioning allogeneic transplantation with a fludarabine-based regime.

S. Papageorgiou, P. Kottaridis, O. Ahmed, 2012, Transplantation.

Supportive Care in the Management of Leukaemia

V. Gant, Eliza Gil, P. Kottaridis, 2015 .

Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.

S. Mackinnon, K. Peggs, R. Hough, 2019, Haematologica.

Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation

R. Tedder, S. Mackinnon, K. Peggs, 2000, British journal of haematology.

reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem

C. Fegan, S. Mackinnon, K. Peggs, 2008 .

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

C. Craddock, C. Fegan, S. Mackinnon, 2002, Blood.

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

R. Hills, D. Linch, A. Burnett, 2005, Blood.

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.

S. Langabeer, D. Linch, D. Bowen, 2002, Blood.

Allogeneic stem cell transplantation as treatment for myelofibrosis

S. Papageorgiou, A. Castleton, P. Kottaridis, 2006, Bone Marrow Transplantation.

Investigations of FLT3 internal tandem duplications in patients with acute myeloid leukaemia

P. Kottaridis, 2006 .

Prognostic Implications of the Presence of FLT3 Mutations in Patients with Acute Myeloid Leukemia

D. Linch, R. Gale, P. Kottaridis, 2003, Leukemia & lymphoma.

The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro

M W Lowdell, J. North, K. Ganeshaguru, 2006, Leukemia.

Relationship between FLT 3 mutation status , biologic characteristics , and response to targeted therapy in acute promyelocytic leukemia

R. Hills, A. Pizzey, K. Mills, 2005 .

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

S. Grace, S. Mackinnon, K. Peggs, 2018, Blood.

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.

A. Mead, S. Mackinnon, K. Peggs, 2010, Blood.

The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation.

S. Grace, S. Mackinnon, P. Travers, 2010, Blood.

lymphoproliferative disorders comparison between 2 prospective studies in patients with Nonmyeloablative transplantation with or without alemtuzumab

J. Miguel, C. Craddock, D. Linch, 2013 .

NON-MYELOABLATIVE TRANSPLANTS WITH OR WITHOUT CAMPATH-1H: COMPARISON BETWEEN TWO PROSPECTIVE STUDIES IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS.

Dolores, J. Garcia-conde, C. Craddock, 2002 .

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

N. Russell, B. Shaw, P. Gandhi, 2011, Bone Marrow Transplantation.

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

C. Craddock, A. Khwaja, D. Grimwade, 2013, British journal of haematology.

transcription-independent mechanism p53-mediated apoptosis of CLL cells: evidence for a

L. Vassilev, A. Hoffbrand, A. Prentice, 2013 .

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.

L. Vassilev, A. Hoffbrand, R. Wickremasinghe, 2008, Blood.

The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

J. Delgado, J. Sierra, R. Benjamin, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cavernosal arterial insufficiency and erectile dysfunction in recipients of high-dose chemotherapy and total body irradiation for multiple myeloma

W. Lees, D. Ralph, R. Chatterjee, 2000, The Lancet.

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

N. Potter, C. Craddock, N. Russell, 2022, Blood.

Reduced intensity transplantation: where are we now?

S. Mackinnon, K. Peggs, E. Morris, 2004, The Hematology Journal.

Tumor‐primed natural killer cells from patients with multiple myeloma lyse autologous, NK‐resistant, bone marrow‐derived malignant plasma cells

J. North, E. Katodritou, E. Terpos, 2011, American journal of hematology.

Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).

C. Craddock, S. Mackinnon, K. Peggs, 2002 .

2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.

Mark W Lowdell, Andrew J Steele, Anastasios Chanalaris, 2009, Blood.